Ingredient supplier CJ BIO’s Akkermansia muciniphila postbiotic ingredient became the first strain of its species to receive a New Dietary Ingredient Notification acknowledgement from the U.S. Food and Drug Administration (FDA), the company reported.

Strains of Akkermansia muciniphila have been evidenced to support gut and metabolic health, but none have received acknowledgment from FDA through the NDIN process, instead going through the self-affirmed GRAS process.

BiomeNrich POST M005 is a postbiotic comprised of heat-killed microbes, offering enhanced stability, safety, and efficacy over traditional probiotics.

In a randomized, double-blind, placebo-controlled clinical trial with 92 participants, patients in the treatment group experienced improved measures in muscle strength and function over 12 weeks. Compared to placebo, the treatment group saw a 200% increase in leg strength and a 130% increase in follistatin, a muscle-supporting protein.

“We are pleased to contribute to the growth of the nutrition industry, especially in the areas of muscle health and healthy aging,” CJ BIO stated. “With the completion of NDI, we believe this milestone will create more opportunities for CPG brands to deliver unique and innovative products to the market using BiomeNrich POST M005.”